<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-118224</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Antimicrobial resistance in tuberculosis</dc:title>
<dc:description xml:lang="en">Although drug resistance in tuberculosis is by no means a new problem, multiple drug resistance is a cause of increasing concern. This study investigated first-line drug resistance in Mycobacterium tuberculosis strains isolated in a hospital en¬vironment and strains submitted as the Reference Center from 2000 to 2010. A total of 650 cultures were tested against first-line using the BACTEC MGIT 960 system. Resistance to first-line drugs was detected in 142 strains, (21.85%). A total of 2%  were multiresistant (MDR). Of the strains resistant to first-line drugs, the greatest resistance was found to isoniazid (7.38 %) followed by rifampin and streptomycin (3.85%), pyracinamide (2%), and ethambutol 1.23%. Only one strain was resistant to four drugs. Values. In view of the resistance observed, careful surveillance of drug resistance is recommended (AU)</dc:description>
<dc:creator>Casal, Manuel</dc:creator>
<dc:creator>Ruiz, Pilar</dc:creator>
<dc:creator>Gutiérrez-Aroca, Juan Basutista</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La resistencia a fármacos en tuberculosis no es un proble¬ma nuevo, pero la resistencia múltiple a los fármacos, despier¬ta cada día más interés. Nuestro estudio consistió en investi¬gar las resistencias a fármacos de las cepas de Mycobacterium tuberculosis aisladas en nuestro hospital Universitario que funciona como centro de referencia para el control de la tu¬berculosis en Andalucía, en el periodo 2001-2010. Hemos es¬tudiado las resistencias en 650 cultivos frente a los fármacos de primera y línea usando el sistema BACTEC MGIT 960. Detec¬tamos resistencias a 1ª línea en 142 cepas, (21,85%). De estas cepas la mayor resistencia se detectó isoniazida (7,38%) segui¬da de rifampicina y estreptomicina (3,85%), pirazinamida (2%), y etambutol (1,23%). En el caso de las cepas multirresistentes (MDR), estos valores son del 2%. Se encontró una cepa con resistencia a los cuatro fármacos. Las resistencias detectadas, aconsejan una vigilancia de las resistencias a los fármacos en tuberculosis (AU)</dc:description>
<dc:source>Rev Esp Quimioter;26(4): 332-336, dic. 2013. tab</dc:source>
<dc:identifier>ibc-118224</dc:identifier>
<dc:title xml:lang="es">Resistencias a fármacos en Mycobacterium tuberculosis</dc:title>
<dc:subject>^d12705^s22073</dc:subject>
<dc:subject>^d5069^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9362^s22021</dc:subject>
<dc:subject>^d7705^s22044</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d12154^s22073</dc:subject>
<dc:subject>^d7705^s22073</dc:subject>
<dc:subject>^d30997^s22057</dc:subject>
<dc:subject>^d23466^s22073</dc:subject>
<dc:subject>^d9362^s22001</dc:subject>
<dc:subject>^d30997^s22032</dc:subject>
<dc:type>article</dc:type>
<dc:date>201312</dc:date>
</metadata>
</record>
</ibecs-document>
